Employing a minimal immune-histochemical panel comprising TTF-1 and p40 enables reliable subtyping in most NSCLC cases, thus conserving tissue for essential molecular testing of targetable driver mutations. This evidence concerns the gene TTF1 and non-small cell lung carcinoma.